Scripps Health


 

2024 Neuro-Oncology Update: Brain Tumors

922 views
April 2, 2024
Disclaimer: On August 6, 2024, the FDA approved vorasidenib (Voranigo) for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.
0 Comments
Login to view comments. Click here to Login
Clinical Hematology & Oncology 2024